Pharmacogenomic and Circulating Biomarkers for CDK4/6 Inhibitors

NCT07100054 · clinicaltrials.gov ↗

ENROLLING_BY_INVITATION

Status

100

Enrollment

OTHER

Sponsor class

Conditions

CDK4/6 Inhibitor
Breast Cancer
CYP3A4 Protein, Human
Drug Interaction
Pharmacogenetic Testing

Interventions

GENETIC: Whole gene sequencing
OTHER: Drug-drug interaction analysis
OTHER: Biomarker analysis

Sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's